No Data
No Data
No Data
No Data
No Data
Orchard Software Announces New Electronic Support for Antimicrobial Stewardship
CARMEL, Ind., April 4, 2024 /PRNewswire/ -- Today, Orchard Software announced the availability of Antimicrobial Use and Resistance (AUR) reporting to the National Healthcare Safety Network (NHSN), wh
PR NewswireApr 4 11:23 ET
Orchard Therapeutics Announces Launch Plans For Lenmeldy - Quick Facts
RTTNewsMar 20 08:05 ET
Orchard Therapeutics Receives FDA Approval of Lenmeldy (Atidarsagene Autotemcel), the Only Therapy for Eligible Children With Early-onset Metachromatic Leukodystrophy in the U.S.
Orchard Therapeutics today announced the U.S. Food and Drug Administration (FDA) has approved Lenmeldy (atidarsagene autotemcel), formerly known as OTL-200, for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ) or early symptomatic early juvenile (ESEJ)—collectively referred to as early-onset—metachromatic leukodystrophy (MLD).
GlobeNewswireMar 18 15:41 ET
ORI Capital Raises $260 Million for Second Life Sciences Fund
- Fundraise closed above its original target, reflecting strong interest from institutional, strategic and high net worth investors globally ORI Capital today announced the final close of its second fund, ORI Fund II
BusinesswireFeb 22 08:00 ET
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient's own hematopoietic stem cells HURCULES study to
GlobeNewswireFeb 5 07:00 ET
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
BOSTON and LONDON, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients
GlobeNewswireFeb 2 07:00 ET
STD0313 : How can you call yourself a non profit organization with a statement like this........loosely written.....our new therapy provides (3 or 4 forgot) million in benefits to the patient so 14 million .........only 10 million over what we have determined is the actual value to the customer......oh and that is a discount rate
STD0313 : What is wrong with this world
TrytosaveabitOP STD0313: Hehehe! They gotta pay the research bills and pay the staff!
TrytosaveabitOP STD0313: A lot my friend, a lot
No Data
No Data
SpyderCall : Good stuff. As usual.